A citation-based method for searching scientific literature

Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
Times Cited: 63







List of co-cited articles
516 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
536
38

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
444
34

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
645
34


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
31

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
826
31

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
31

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
360
28

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
385
23

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
296
23

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
445
20

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
345
17

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
903
17

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
682
17

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
422
15

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
566
15

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R E Miller, A Leary, C L Scott, V Serra, C J Lord, D Bowtell, D K Chang, D W Garsed, J Jonkers, J A Ledermann,[...]. Ann Oncol 2020
86
15

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Kirsten M Timms, Victor Abkevich, Elisha Hughes, Chris Neff, Julia Reid, Brian Morris, Saritha Kalva, Jennifer Potter, Thanh V Tran, Jian Chen,[...]. Breast Cancer Res 2014
207
14

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Barbara M Norquist, Mark F Brady, Maria I Harrell, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Robert A Burger, Krishnansu S Tewari,[...]. Clin Cancer Res 2018
110
14

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.
Arielle L Heeke, Michael J Pishvaian, Filipa Lynce, Joanne Xiu, Jonathan R Brody, Wang-Juh Chen, Tabari M Baker, John L Marshall, Claudine Isaacs. JCO Precis Oncol 2018
154
14

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Theo A Knijnenburg, Linghua Wang, Michael T Zimmermann, Nyasha Chambwe, Galen F Gao, Andrew D Cherniack, Huihui Fan, Hui Shen, Gregory P Way, Casey S Greene,[...]. Cell Rep 2018
421
14

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
100
14

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Johnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, Andrew N J Tutt. Breast Cancer Res 2014
176
12

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
685
12

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
12

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley,[...]. Nat Commun 2020
81
12

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
212
12

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
852
12

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.
Zsofia Sztupinszki, Miklos Diossy, Marcin Krzystanek, Lilla Reiniger, István Csabai, Francesco Favero, Nicolai J Birkbak, Aron C Eklund, Ali Syed, Zoltan Szallasi. NPJ Breast Cancer 2018
67
12

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
11

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
11

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, Philip C Schouten, Matty Meijers, Natalja T Ter Haar, Vincent T H B M Smit, Remi A Nout, Mark A Glaire, David N Church,[...]. Clin Cancer Res 2019
69
11

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
11

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
106
11

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Andrea M Marquard, Aron C Eklund, Tejal Joshi, Marcin Krzystanek, Francesco Favero, Zhigang C Wang, Andrea L Richardson, Daniel P Silver, Zoltan Szallasi, Nicolai J Birkbak. Biomark Res 2015
125
11

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Br J Cancer 2018
87
11

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
104
9

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
173
9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
9

Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
136
9

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
99
9

Copy number signatures and mutational processes in ovarian carcinoma.
Geoff Macintyre, Teodora E Goranova, Dilrini De Silva, Darren Ennis, Anna M Piskorz, Matthew Eldridge, Daoud Sie, Liz-Anne Lewsley, Aishah Hanif, Cheryl Wilson,[...]. Nat Genet 2018
155
9

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
825
9

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
9

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
629
9

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
121
9

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
10
60

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
83
9

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
205
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.